scholarly journals The role of increased levels of homocysteine in the development of cardiovascular diseases

2006 ◽  
Vol 59 (3-4) ◽  
pp. 143-147 ◽  
Author(s):  
Zoran Ceperkovic
Keyword(s):  
Folic Acid ◽  
Amino Acid ◽  
Cardiovascular Diseases ◽  
Vitamin B12 ◽  
Vitamin B6 ◽  
Heart Diseases ◽  
Daily Intake ◽  
Cholesterol Oxidation ◽  
Total Risk ◽  
Homocysteine Concentration

Introduction. Homocysteine is a sulphur amino acid produced by demethylation of the essential amino acid methionine. Dysfunction of certain enzymes or insufficient intake of nutrients may cause increase of intracellular homocysteine, which is then exported into plasma. Etiopathogenesis of cardiovascular diseases accompanied with higher level of homocysteine. McCully's theory suggests that high levels of homocysteine are associated with cardiovascular diseases, arteriosclerosis and endothelial dysfunction. Harmful effects of homocysteine are associated with LDL cholesterol oxidation, increased production of collagen, lower availability of nitric oxide as well as prothrombotic activity. Reduction of homocysteine levels. The most recent researches show that hyperhomocysteinemia is responsible for about 10% of total risk of cardiovascular diseases. Vitamin BJ2 plays a major role in the remethylation of homocysteine. Reducing the homocysteine concentration in blood by 3 mol/l (with daily intake of 0.8 mg of folic acid) reduces the risk of ishemic heart diseases by 16%, vein thrombosis by 25%, and stroke by 24%. A six-month therapy with folic acid (Img/d), vitamin B12 (400g/d) and vitamin B6 (10mg/d), reduces the frequency of cardiovascular occurrences after successful PTCA. Plasma homocysteine concentration over 12/1 doubles the risk of myocardial infarction. Conclusion. A lack of folates, vitamin B6 and vitamin B12 increases the level of homocysteine and thus increases the risk of cardiovascular diseases. Changes in lifestyle and diet, as well as intake of food supplements, are of great importance in reducing homocysteine levels in plasma and therefore in reducing the occurrence and acceleration of arteriosclerosis. .

scholarly journals Blood homocysteine, folic acid, vitamin B12 and vitamin B6 levels in psoriasis patients

TURKDERM ◽  
2017 ◽  
pp. 92-97
Author(s):  
Meltem Uslu ◽  
Neslihan Şendur ◽  
Ekin Şavk ◽  
Aslıhan Karul ◽  
Didem Kozacı ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Vitamin B6

scholarly journals Plasma Vitamin B6 Vitamers before and after Oral Vitamin B6 Treatment: A Randomized Placebo-controlled Study

2003 ◽  
Vol 49 (1) ◽  
pp. 155-161 ◽  
Author(s):  
Mustafa Vakur Bor ◽  
Helga Refsum ◽  
Marianne R Bisp ◽  
Øyvind Bleie ◽  
Jorn Schneede ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Vitamin B6 ◽  
Oral Treatment ◽  
Prolonged Treatment ◽  
Controlled Study ◽  
Plasma Vitamin ◽  
Additional Increase ◽  
Before And After ◽  
B Vitamin

Abstract Background: Vitamin B6 has attracted renewed interest because of its role in homocysteine metabolism and its possible relation to cardiovascular risk. We examined the plasma B6 vitamers, pyridoxal 5′-phosphate (PLP), pyridoxal (PL), pyridoxine (PN), and 4-pyridoxic acid (4-PA) before and after vitamin B6 supplementation. Methods: Patients (n = 90; age range, 38–80 years) undergoing coronary angiography (part of the homocysteine-lowering Western Norway B-Vitamin Intervention Trial) were allocated to the following daily oral treatment groups: (A), vitamin B12 (0.4 mg), folic acid (0.8 mg), and vitamin B6 (40 mg); (B), vitamin B12 and folic acid; (C), vitamin B6; or (D), placebo. EDTA blood was obtained before treatment and 3, 14, 28, and 84 days thereafter. Results: Before treatment, PLP (range, 5–111 nmol/L) and 4-PA (6–93 nmol/L) were the predominant B6 vitamers identified in plasma. During the 84-day study period, the intraindividual variation (CV) in patients not treated with vitamin B6 (groups B and D) was 45% for PLP and 67% for 4-PA. Three days after the start of treatment, the increases in concentration were ∼10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively. No significant additional increase was observed at the later time points. The PLP concentration correlated to the concentrations of 4-PA and PL before treatment, but not after treatment. The PL concentration correlated with 4-PA before and after treatment. Conclusions: Vitamin B6 treatment has an immediate effect on the concentrations and the forms of B6 vitamers present in plasma, and the changes remain the same during prolonged treatment. Our results suggest that the B6 vitamers in plasma reflect vitamin B6 intake.

scholarly journals Prevalence of Anemia and Related Deficiencies in the First Year following Laparoscopic Gastric Bypass for Morbid Obesity

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
E. O. Aarts ◽  
B. van Wageningen ◽  
I. M. C. Janssen ◽  
F. J. Berends
Keyword(s):  
Morbid Obesity ◽  
Gastric Bypass ◽  
Folic Acid ◽  
Vitamin B12 ◽  
Daily Intake ◽  
First Year ◽  
Folic Acid Deficiency ◽  
Morbid Obese ◽  
Iron Folic Acid ◽  
Prevalence Of Anemia

Background. Anemia associated with deficiencies in iron, folic acid, and vitamin B12 are very common after Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) surgery for morbid obesity. This study was conducted to evaluate the prevalence of anemia after LRYGB.Patients and Methods. A total of 377 morbid obese patients were included in our study. All patients underwent a LRYGB. Hematologic parameters were obtained prior to and after surgery on standardized time intervals.Results. Anemia was present in 21 (P=0.02) patients after surgery. Iron, folic acid, and vitamin B12 deficiencies were diagnosed in 66%, 15%, and 50% of patients, respectively. In 86% of patients, anemia was accompanied by one of these deficiencies.Conclusion. These results show that anemia and deficiencies for iron, folic acid deficiency, and vitamin B12 are very common within the first year after LRYGB. We advise a minimal daily intake of 65 mg of iron in male and 100 mg in female patients, 350 μg of vitamin B12, and 400 μg of folic acid. Patients undergoing LRYGB must be closely monitored for deficiencies pre- and postoperative and supplemented when deficiencies occur.

Bread fortification with folic acid, vitamin B12, and vitamin B6 in Hungary

The Lancet ◽  
1998 ◽  
Vol 352 (9135) ◽  
pp. 1225 ◽  
Author(s):  
Andrew E Czeizel ◽  
Zoltan Merhala
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Vitamin B6

Optimization of folic acid, vitamin B12, and vitamin B6 supplements in pediatric patients with sickle cell disease

2002 ◽  
Vol 69 (4) ◽  
pp. 239-246 ◽  
Author(s):  
Fey P.L. van der Dijs ◽  
M. Rebecca Fokkema ◽  
D.A. Janneke Dijck-Brouwer ◽  
Bram Niessink ◽  
Thaliet I.C. van der Wal ◽  
...  
Keyword(s):  
Folic Acid ◽  
Sickle Cell Disease ◽  
Vitamin B12 ◽  
Sickle Cell ◽  
Vitamin B6 ◽  
Pediatric Patients ◽  
Cell Disease

Homocysteine in the Plasma of Renal Transplant Recipients: Effects of Cofactors for Methionine Metabolism

1981 ◽  
Vol 61 (6) ◽  
pp. 743-749 ◽  
Author(s):  
D. E. L. Wilcken ◽  
Vatsala J. Gupta ◽  
A. K. Betts
Keyword(s):  
Folic Acid ◽  
Amino Acid ◽  
Renal Transplant ◽  
Serum Creatinine ◽  
Vitamin B12 ◽  
Normal Subjects ◽  
Serum Folate ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Erythrocyte Folate

1. Homocysteine which is formed during the metabolism of methionine is readily oxidized and is measured by the amino acid analyser as cysteine—homocysteine mixed disulphide and homocystine. We measured plasma amino acid concentrations after an overnight fast in 27 stable long-term renal transplant recipients and 25 age-and sex-matched normal subjects with particular emphasis on sulphur-containing amino acids. 2. Plasma cysteine—homocysteine mixed disulphide was increased in the patients (mean 6.0 ± sd 3.2 μmol/l; normal 3.1 ± 0.9 μmol/l, P < 0.001) and homocystine was detectable in low concentration (< 1.0 μmol/l) in 24; the elevation in cysteine—homocysteine was related to serum creatinine (r = 0.60, P < 0.002). Cystine was also increased (91.6 ± 29.3 μmol/l; normal subjects 64.0 ± 16.7 μmol/l, P < 0.001), but methionine concentrations were normal. 3. When pyridoxine, folic acid and vitamin B12, cofactors for homocysteine metabolism, were administered sequentially to 11 arbitrarily selected transplant recipients cysteine—homocysteine decreased from 7.3 ± 2.1 to 4.3 ± 0.8 μmol/l (P < 0.001) and homocystine became undetectable. the response coincided with the giving of folic acid and occurred without alteration in serum creatinine and with normal serum folate and vitamin B12 concentrations. 4. in eight patients in whom pretreatment erythrocyte folate was measured, folic acid therapy reduced cysteine—homocysteine from 9.0 ± 3.1 to 5.4 ± 1.6 μmol/l over a 4 week period (P < 0.001), the largest response being in the one patient with subnormal erythrocyte folate; values were in the low-normal or normal range in the other seven. 5. We conclude that plasma homocysteine is increased in renal transplant recipients when serum creatinine is only moderately elevated and that the homocysteine concentrations are decreased by treatment with folic acid, suggesting that both reduced homocysteine excretion and relative shortages of folic acid are responsible.

scholarly journals Método espectrofotométrico para a determinação de L(+) Arginina, L(-) Asparagina e L(+) Lisina com o-diacetilbenzol, em especialidades farmacêuticas

1982 ◽  
Vol 4 (4) ◽  
pp. 37
Author(s):  
Eunice Maria Maffini Antoniazzi ◽  
Maria Elisabeth do Canto Vinadé
Keyword(s):  
Amino Acids ◽  
Folic Acid ◽  
Amino Acid ◽  
Relative Error ◽  
Vitamin B6 ◽  
Vitamin B1 ◽  
Direct Determination ◽  
The Other ◽  
Pharmaceutical Drugs ◽  
Vitamin B2

In this work the main analytical parameters for a spectrophotometric method of amino-acid analysis were determined.The Ringbom curve for L (+) Arginin (550 nm), L (-) Asparing (547 mn) and L (+) Lysin (547 mn) determination with o-diacetylbenzene showed different values for concentrations.The best rang of concentration was: L (+) Arginin 150 to 500µg/ml with a relative error of 5.26%; L (-) Asparagin 40 to 200µg/ml with relative error 1.43%; L (+) Lysin 8 to 44µg/ml with a relative error of 0.18%.Among the different compounds studied, it was observed the absorptions of the tiamin cloride (Vitamin B1), riboflavin choride (Vitamin B2), piridoxin cloride (Vitamin B6), carnitin, buclisin, folic acid and nicotinamide and that this compound in presence of o-diacetylbenzene do not interfere with the absorptions of the amino-acids L (+) Arginin, L (-) Asparagin and L (+) Lysin during their determination. On the other hand, the absorption of the compounds cianocobalamin and ɤ aminbutiric acid or the absorptions of these compounds in presence of o-diacetylbenzene interfere with absorptions of the aminoacids studied.The absorption spectra of these three pharmaceutical drugs was obtained with o-diacetylbenzene and we found out the possibility of their direct determination by the method described.

Sign in / Sign up

Export Citation Format

Share Document